Generate Biomedicines, Inc. GENB
13.85 USD +0.64 (+4.84%)
At closeNov 3, 2026, 4:41 PM EST
13.90 +0.05 +0.36%
After hours · Nov 3, 4:41 PM ET
13.33 Day range 14.17
11.00 52-week range 22.67
- YTD
- +9.49%
- 1 year
- +9.49%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +94.9% upside
Now 13.85
- Target (low)
- 22.00
- Target (mean)
- 27.00
- Target (high)
- 30.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.545 | -0.67 – -0.44 | 0.00 | 0.0% | 7.75M | 0.0% | 4 |
| Next quarter | -0.5675 | -0.63 – -0.44 | 0.00 | 0.0% | 7.65M | 0.0% | 4 |
| Current year | -2.30 | -2.50 – -2.14 | 0.00 | 0.0% | 29.68M | 0.0% | 4 |
| Next year | -2.28 | -2.72 – -1.53 | -2.30 | +0.9% | 23.83M | -19.7% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 28, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 24, 2026 | Goldman Sachs | Initiated | — | Buy |
| Mar 24, 2026 | Morgan Stanley | Initiated | — | Overweight |
| Mar 24, 2026 | Piper Sandler | Initiated | — | Overweight |
| Mar 24, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 24, 2026 | Guggenheim | Initiated | — | Buy |